Tag: Tavr

Following transcatheter aortic valve replacement (TAVR), balancing the risk of ischemic events with the risk of major bleeding is crucial, with recent meta-analyses showing that dual antiplatelet therapy (DAPT) is associated with an increased risk of bleeding compared with single antiplatelet therapy (SAPT). The optimal duration of antiplatelet therapy after TAVR has shifted significantly, moving away from prolonged dual-therapy regimens for most patients.

A patient with a mechanical aortic valve will require lifelong anticoagulation, while those with bioprosthetic valves typically need it only for a short period or not at all. The question, **does aortic valve replacement require anticoagulation**, is crucial for patient safety, as it depends heavily on the specific valve and procedural factors.

Following an aortic valve replacement, the medication regimen is highly individualized and critical for a successful recovery. The specific **medication is given after aortic valve replacement** depends on the type of valve implanted, patient comorbidities, and the procedure type (surgical or transcatheter).

Following a Transcatheter Aortic Valve Replacement (TAVR), roughly 50% of strokes occur within the first 30 days, underscoring the importance of antithrombotic therapy. The question of how long do you have to take blood thinners after TAVR is complex and depends heavily on each patient's specific risk profile for both bleeding and clotting.